Description
ADCC-Enhanced anti-CD38 (38SB) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Hematologic malignancies
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD38 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD38
Full Name
CD38 molecule
Background
CD38 is a novel multifunctional ectoenzyme widely expressed in cells and tissues especially in leukocytes. CD38 also functions in cell adhesion, signal transduction and calcium signaling.
Alternative Names
CD38; CD38 molecule; T10; ADPRC 1; ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1; cADPr hydrolase 1; CD38 antigen (p45); NAD(+) nucleosidase; ADP-ribosyl cyclase 1; cyclic ADP-ribose hydrolase 1; 2-phospho-ADP-ribosyl cyclase; 2-phospho-cyclic-ADP-ribose transferase; 2-phospho-ADP-ribosyl cyclase/2-phospho-cyclic-ADP-ribose transferase
Gene ID
952
UniProt ID
Q5ZPR3
Cellular Localization
Membrane
Involvement in Disease
Diseases associated with CD38 include Richter's Syndrome and Prolymphocytic Leukemia.
Related Pathways
Its related pathways are Calcium signaling pathway and Cell-type Dependent Selectivity of CCK2R Signaling.
Function
Synthesize the second messenger ring adp-ribose and nicotinic acid-adenine dinucleotide phosphate, the former is the second messenger of glucose-induced insulin secretion. Also has cADPr hydrolase activity. It is also a receptor in the cells of the immune system.
Field of research
Cancer antibody; Developmental Biology antibody; Immune System antibody; Metabolism antibody; Pro-B Cell Marker antibody; Pre-B Cell Marker antibody
Post-translational modifications
1.Glycosylation at Asn100, Asn164, Asn209, and Asn219 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
38SB
Description
This product is an investigational naked monoclonal antibody that selectively binds to CD38 and disrupts intracellular signaling in preclinical studies. This product is currently being investigated in phase I trials in multiple myeloma in combination with lenalidomide and dexamethasone and as a monotherapy in selected CD38+ hematological malignancies.
Antibody Indication
Hematologic malignancies
